A Study Of TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-10-02
Target enrollment:
Participant gender:
Summary
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies to treat
participants who have relapsed or refractory multiple myeloma.
The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination
with anti-CD38 monoclonal antibodies.
Participants will be on this combination treatment for 28-day cycles. They will continue with
this treatment until disease progression or unacceptable toxicity.